Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of

Related Keywords

Germany ,United States ,Ankara ,Turkey ,United Kingdom ,France ,Spain ,Lucie Larguier ,Christophe Le Tourneau ,Le Tourneau ,Ben Brahim ,Transgene Euronext ,Sylvie Berrebi George Underwood ,Maud Brandely ,Head Of The Department Drug Development ,Twitter ,Data Monitoring Committee ,Curie Institute ,Pfizer ,Astrazeneca ,Merck Kga ,Pfizer Inc ,Corporate Communications ,Merck Kgaa ,Euronext Paris ,Independent Data Monitoring Committee ,Chief Medical Officer ,Hedi Ben Brahim ,Chief Executive Officer ,Modified Vaccinia Ankara ,Drug Development ,Principal Investigator ,Artificial Intelligence ,Risk Factors ,Universal Registration Document ,Human Papilloma Virus ,Human Papillomavirus ,Transgene ,Nnounces ,Positive ,Interim ,Analysis ,Results ,Hase ,Trial ,Valuating ,Tg4001 ,Avelumab ,Anogenital ,Cancers ,